Skip to main content

Table 4 Most frequently (≥3% of patients) reported adverse events

From: Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia

System Organ Class

Preferred Term, n (%)

NGX-4010

(n = 102)

Control

(n = 53)

Number of Patients Reporting 1 or More Adverse Events

76 (75%)

28 (53%)

Gastrointestinal Disorders

10 (10%)

4 (8%)

   Nausea

5 (5%)

1 (2%)

General Disorders and Administration Site Conditions

38 (37%)

12 (23%)

   Application Site Burning

3 (3%)

0

   Application Site Discoloration

0

3 (6%)

   Application Site Dryness

10 (10%)

2 (4%)

   Application Site Erythema

4 (4%)

0

   Application Site Pain

4 (4%)

2 (4%)

   Application Site Papules

4 (4%)

2 (4%)

   Application Site Pruritus

17 (17%)

6 (11%)

   Application Site Swelling

10 (10%)

1 (2%)

   Application Site Urticaria

3 (3%)

0

   Application Site Vesicles

5 (5%)

1 (2%)

   Pain Exacerbated

3 (3%)

0

Infections and Infestations

16 (16%)

8 (15%)

   Bronchitis

3 (3%)

0

   Herpes Zoster

3 (3%)

2 (4%)

   Upper Respiratory Tract Infection

1 (1%)

2 (4%)

Injury, Poisoning and Procedural Complications

4 (4%)

6 (11%)

   Injury

1 (1%)

2 (4%)

Musculoskeletal and Connective Tissue Disorders

10 (10%)

2 (4%)

   Back Pain

3 (3%)

1 (2%)

Nervous Systems Disorders

5 (5%)

5 (9%)

   Dizziness

1 (1%)

3 (6%)

Respiratory, Thoracic and Mediastinal Disorders

12 (12%)

4 (8%)

   Cough

3 (3%)

0

   Nasal Congestion

1 (1%)

2 (4%)

   Nasopharyngitis

3 (3%)

2 (4%)

Vascular Disorders

5 (5%)

1 (2%)

   Hypertension

3 (3%)

0